An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Healthpeak Properties, Inc.
VERDICT
The label
Markup
read at $22.51
Healthpeak Properties holds its Markup at $22.51.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · does not pass the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 13 days
Price
$22.51
Valuation
70.34 trailing · -150.07 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.00
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads AVOID — it trades above our $22.00 fair value estimate, narrow competitive moat, 7.10% revenue growth.
Read at
$22.51
70.34 P/E · -150.07 fwd
Our fair value
$22.00
2% premium
Analyst target (avg)
$22.00
-2% to current
Target low $17.00Analyst target rangeTarget high $29.00
▲ current $22.51 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$22.51
you are here
Conservative
$17.00
-24%
Analyst avg
$22.00
-2%
Our fair value
$22.00
-2%
Analyst high
$29.00
+29%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our model and the Street both land near today's price — fairly valued, with no strong edge either way.
Revenue growth
7.10%
Profit margin
7.73%
Debt to equity
118.24
Analyst consensus
Buy · 19 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✗ DOES NOT PASS
Why it fails. The problem is its debt ratio. Because both standards agree on this, it is a clear exclusion, not a borderline case.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is 49.9% of its assets, above the one-third ceiling the screen allows.Fail
Interest-bearing cashCash held in interest-bearing accounts and securities is 3.9% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 2.7% of assets, under the 49% limit.Pass
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Healthcare REIT trips on debt and weak returns
Healthpeak owns medical buildings across the United States. We pass on the name because the shares trade above our fair value and the ethical screen flags the debt ratio straight away.
Revenue rises 7 percent yet the forward multiple has turned negative at minus 150 times while return on equity sits at just 3 percent and profit margins reach only 8 percent. A narrow moat offers little protection when those returns stay this low.
High debt remains the core problem and leaves the business exposed if rates stay elevated or occupancy slips. Nineteen analysts may lean buy but the combination of thin returns and the ethical fail tells us to stay clear.
Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
DOC trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (18 analysts) rates it buy, with a mean price target of $21. Entered 2026-07-26 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-26Markup$22.51+13.7%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (18 analysts) rates it buy, with a mean price target of $21.
2026-07-18Markup$19.79+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 25%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (18 analysts) rates it buy, with a mean price target of $21.
2026-07-03Markup$19.79+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Markup$19.79Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
